Iron Deficiency Treatment Guidelines

Introduction to Iron Deficiency Treatment

• The American Gastroenterological Association and European Society for Medical Oncology recommend oral ferrous sulfate (200 mg twice daily) as the first-line treatment for iron deficiency due to its simplicity, cost-effectiveness, and efficacy, with intravenous iron infusion reserved for cases where oral iron is not tolerated or ineffective 1, 2

Indications for Intravenous Iron Infusion

• Intravenous iron infusion is indicated for patients with intolerance to oral iron, inflammatory bowel disease with active inflammation, those who have undergone bariatric procedures, or have iron-refractory iron-deficiency anemia (IRIDA) due to TMPRSS6 defects, as recommended by the American College of Gastroenterology, National Comprehensive Cancer Network, and European Society of Gastrointestinal Endoscopy 1, 2, 3
• Conditions that affect iron absorption, such as gastropathic hypotension with ongoing bleeding, also require intravenous iron infusion 1

Benefits of Intravenous Iron Infusion

• Intravenous iron infusion provides a faster correction of hemoglobin levels, especially in patients with chronic inflammation, and reduces the need for transfusions in patients with cancer, as stated by the American Society of Clinical Oncology, National Institute for Health and Care Excellence, and European Hematology Association 2, 4
• Intravenous iron infusion combined with erythropoiesis-stimulating agents results in a better hematopoietic response in patients with cancer 4

Available Formulations and Safety

• Available formulations include iron saccharose (Venofer), carboxymaltose iron (Ferinject), and iron dextran (Cosmofer), each with different administration protocols and dosages, as noted by the American Academy of Clinical Toxicology 2
• The European Medicines Agency and American Heart Association warn of similar risks with all intravenous formulations, including true anaphylaxis and pseudoallergic reactions, and recommend having resuscitation facilities available during administration 1, 2

Monitoring and Evaluation

• The International Society for the Study of Iron in Biology and Medicine and European Society for Medical Oncology advise monitoring ferritin concentrations to avoid iron overload and possible side effects, such as hypophosphatemia with carboxymaltose iron 3
• The response to treatment should be evaluated after 4-8 weeks, and intravenous therapy considered if there is no adequate response, as recommended by the European Society of Gastrointestinal Endoscopy 2

Treatment Guidelines

• The American College of Physicians, National Institute for Health and Care Excellence, and American Gastroenterological Association recommend documenting complete iron studies, identifying the underlying cause of iron deficiency, and using oral ferrous sulfate as the first-line treatment, with consideration of lower doses if intolerance occurs, and adding vitamin C to improve absorption 1, 2
• The National Comprehensive Cancer Network recommends intravenous iron products alone for iron repletion in patients with cancer with absolute iron deficiency, and using erythropoiesis-stimulating agents in addition to intravenous iron for patients with functional iron deficiency 4
• Intravenous iron therapy is medically indicated for adult patients with iron deficiency anemia who have intolerance to oral iron or have had an unsatisfactory response to oral iron, and should only be considered after documented failure of oral therapy or if specific contraindications to oral therapy exist, as stated by the American Gastroenterological Association and 5

2